National Healthcare Security Administration / 国家医保局
The National Healthcare Security Administration / 国家医保局 appears in 130. 谁才是生物医药行业发展的核心驱动力？兼谈创新药产业链的角色分工 as the payer-side actor in China’s innovation-drug ecosystem. The source names reimbursement and medical-insurance payment as part of the industry structure because approval alone does not create broad patient access or commercial return.
Connections
- Unmet Medical Need Demand Pull - patient demand becomes investable only when payment and access channels exist.
- Clinical Development Capability - trial evidence and real clinical benefit matter for reimbursement as well as approval.
- China Biotech Globalization - global commercial capability includes payer and market-access work, not only sales teams.